Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53).

abstract：:To identify the differentially expressed genes (DEGs) and their transcription factors (TFs) in colorectal cancer (CRC). We performed an integrated analysis of microarray studies. Functional annotation and CRC-specific transcriptional regulatory network construction were performed. Expression of selected DEGs and TFs w...

journal_title：Cancer gene therapy

authors： Liu HY,Zhang CJ

更新日期：2017-06-01 00:00:00

abstract：:Intratumoral injection of recombinant adenoviral type 5 (Ad5) vectors that carry prodrug-activating enzymes like DT-diaphorase (DTD) could be used to selectively target tumor cells for chemotherapy. To demonstrate the feasibility of this approach, Ad5 vectors were constructed, which express human DTD minigenes for bot...

journal_title：Cancer gene therapy

authors： Misra V,Klamut HJ,Rauth AM

更新日期：2002-02-01 00:00:00

abstract：:Sarcomas, or tumors of connective tissue, represent roughly 20% of childhood cancers. Although the cure rate for sarcomas in general has significantly improved in the last 10 years, there continue to be subgroups that are difficult to treat. High-grade or metastatic soft-tissue sarcomas and rhabdomyosarcomas (RMS) of ...

journal_title：Cancer gene therapy

authors： Ganjavi H,Gee M,Narendran A,Freedman MH,Malkin D

更新日期：2005-04-01 00:00:00

abstract：:Various therapeutic approaches toward killing glioma cells by inducing apoptosis have been developed, but these approaches are often hampered by anti-apoptotic mechanisms. In this study, we attempted to develop a technique that overrides the resistance toward apoptosis in glioma cells. To date, p53- and Fas-mediated a...

journal_title：Cancer gene therapy

authors： Shinoura N,Yoshida Y,Asai A,Kirino T,Hamada H

更新日期：2000-05-01 00:00:00

abstract：:Recurrent or metastatic cancer in most cases remains an incurable disease, and thus alternative treatment strategies, such as oncolytic virotherapy, are of great interest for clinical application. Oncolytic adenoviruses (Ads) have many advantages as virotherapeutic agents and have been safely employed in the clinics. ...

journal_title：Cancer gene therapy

authors： Choi IK,Yun CO

更新日期：2013-02-01 00:00:00

abstract：:Engineered retroviruses are widely used vectors for cancer gene therapy approaches. However, the ability to target cells of therapeutic interest while controlling the expression of the transferred genes would improve both the efficiency and the safety of viral vectors. In this study, we investigated the ability of a r...

journal_title：Cancer gene therapy

authors： Nguyen TH,Loux N,Dagher I,Vons C,Carey K,Briand P,Hadchouel M,Franco D,Jouanneau J,Schwall R,Weber A

更新日期：2003-11-01 00:00:00

abstract：:Despite the fact that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can selectively induce apoptosis in cancer cells, TRAIL resistance in cancer cells has challenged the use of TRAIL as a therapeutic agent. First, prostate carcinoma cell lines (DU145, LNCaP and PC3) were screened for sensitivity to a...

journal_title：Cancer gene therapy

authors： Sanlioglu AD,Koksal IT,Karacay B,Baykara M,Luleci G,Sanlioglu S

更新日期：2006-01-01 00:00:00

abstract：:Most cancer vaccines to date have made use of common tumor antigens or allogenic cancer cell lines. The majority of tumor antigens may, however, be unique patient-specific antigens. Dendritic cells (DCs) are the most potent antigen-presenting cells known. The present report is a full-scale preclinical evaluation of au...

journal_title：Cancer gene therapy

authors： Kyte JA,Kvalheim G,Aamdal S,Saebøe-Larssen S,Gaudernack G

更新日期：2005-06-01 00:00:00

abstract：:We examined the host immune response to the poorly immunogenic B16-BL6 melanoma, which was transduced to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) (450 ng/10(6)/24 h). Tumor growth after subcutaneous inoculation was not significantly altered, although an influx of neutrophils and monocytes/macr...

journal_title：Cancer gene therapy

authors： Arca MJ,Krauss JC,Aruga A,Cameron MJ,Shu S,Chang AE

更新日期：1996-01-01 00:00:00

abstract：:Gene-directed enzyme prodrug therapy (GDEPT) is a promising approach to local management of cancer through targeted chemotherapy. Killing localized tumors by GDEPT in a manner that induces strong antitumor cellular immune responses might improve local management and allow benefit in disseminated cancer. Here we evalua...

journal_title：Cancer gene therapy

authors： Djeha HA,Todryk SM,Pelech S,Wrighton CJ,Irvine AS,Mountain A,Lipinski KS

更新日期：2005-06-01 00:00:00

abstract：:Hepatocellular carcinoma (HCC) recurrence is one of the leading causes of death after orthotopic liver transplantation (OLT). The sixth complement component (C6) is a late-acting complement protein that participates in the assembly of the membrane attack complex, which has an indispensable role in innate and acquired ...

journal_title：Cancer gene therapy

authors： Wang Z,Liao J,Wu S,Li C,Fan J,Peng Z

更新日期：2016-06-01 00:00:00

abstract：:At the Eleventh International Conference on Gene Therapy of Cancer (December 12-14, 2002, San Diego, CA) progress on using gene transfer technology to treat cancer was presented. Although there is as yet no cancer gene therapy being marketed, considerable progress has been made in defining likely strategies and likely...

journal_title：Cancer gene therapy

authors： Gottesman MM

更新日期：2003-07-01 00:00:00

abstract：:The success of cancer gene therapies requiring in vivo gene transfer is severely hampered by the low efficacy of gene transfer, which has been difficult to improve. We therefore established a novel strategy to increase the share of transduced cells post gene transfer. We hypothesized that in vivo selection of tumor ce...

journal_title：Cancer gene therapy

authors： Unger MM,Wahl J,Ushmorov A,Buechele B,Simmet T,Debatin KM,Beltinger C

更新日期：2007-01-01 00:00:00

abstract：:Oncolytic adenoviruses are promising anticancer agents. To study and optimize their tumor-killing potency, genuine tumor models are required. Here we describe the use of the chicken chorioallantoic membrane (CAM) tumor model in studies on oncolytic adenoviral vectors. Suspensions of human melanoma, colorectal carcinom...

journal_title：Cancer gene therapy

authors： Durupt F,Koppers-Lalic D,Balme B,Budel L,Terrier O,Lina B,Thomas L,Hoeben RC,Rosa-Calatrava M

更新日期：2012-01-01 00:00:00

abstract：:Targeting tumor vasculature represents an interesting approach for the treatment of solid tumors. The alpha v beta 3 integrins have been found to be specifically associated with angiogenesis in tumors. By using bacteriophage display technology, Ruoslahti et al found that a group of peptides containing the RGD (Arg-Gly...

journal_title：Cancer gene therapy

authors： Li J,Ji J,Holmes LM,Burgin KE,Barton LB,Yu X,Wagner TE,Wei Y

更新日期：2004-05-01 00:00:00

abstract：:Histological grading (HG) is an important prognostic factor of colorectal adenocarcinoma (CRAC): the high-grade CRAC patients have poorer prognosis after tumor resection. Especially, the high-grade stage II CRAC patients are recommended to receive adjuvant chemotherapy. Due to the subjective nature of HG assessment, i...

journal_title：Cancer gene therapy

authors： Zheng H,Song K,Fu Y,You T,Yang J,Guo W,Wang K,Jin L,Gu Y,Qi L,Zhao W,Guo Z

更新日期：2020-09-01 00:00:00

abstract：:Sodium iodide symporter (NIS) reporter gene imaging is an excellent technology for noninvasive cell fate determination in living animals unless the NIS-transduced cells reside in perigastric organs such as the spleen, liver, diaphragm, omentum, pancreas, perigastric lymph nodes or perigastric tumor deposits. Here we r...

journal_title：Cancer gene therapy

authors： Suksanpaisan L,Pham L,McIvor S,Russell SJ,Peng KW

更新日期：2013-11-01 00:00:00

abstract：:Adenovirus (Adv)-mediated herpes simplex virus thymidine kinase (adv/tk) gene therapy combined with ganciclovir (GCV) medication is a promising approach for the treatment of malignant glioma. However, optimal administration and the effect of possible adjuvant treatments have not been fully examined. In the present stu...

journal_title：Cancer gene therapy

authors： Tyynelä K,Sandmair AM,Turunen M,Vanninen R,Vainio P,Kauppinen R,Johansson R,Vapalahti M,Ylä-Herttuala S

更新日期：2002-11-01 00:00:00

abstract：:Apatinib, a selective vascular endothelial growth factor receptor 2-tyrosine kinase inhibitor, has demonstrated activity against a wide range of solid tumors, including advanced hepatocellular carcinoma (HCC). Preclinical and preliminary clinical results have confirmed the synergistic antitumor effects of apatinib in ...

journal_title：Cancer gene therapy

authors： Yang Y,Wang C,Sun H,Jiang Z,Zhang Y,Pan Z

更新日期：2020-06-12 00:00:00

abstract：:We present here the updated results after 9 years of the beginning of a trial on canine patients with malignant melanoma. This surgery adjuvant approach combined local suicide gene therapy with a subcutaneous vaccine composed by tumor cells extracts and xenogeneic cells producing human interleukin-2 and granulocyte-ma...

journal_title：Cancer gene therapy

authors： Finocchiaro LM,Glikin GC

更新日期：2012-12-01 00:00:00

abstract：:We have constructed and tested five recombinant adenoviruses (Ads) that express a variety of immunomodulators, including CD40 ligand (CD40L), a potent costimulator of several components of the immune system. We demonstrate that CD40L expressed from Ad in K1735 mouse melanoma cells leads to a strong reduction in tumori...

journal_title：Cancer gene therapy

authors： Peter I,Nawrath M,Kamarashev J,Odermatt B,Mezzacasa A,Hemmi S

更新日期：2002-07-01 00:00:00

abstract：:Malignant tumors express tumor-related antigens, but effective antitumor immunity does not occur in the primary host. One hypothesis is that there is insufficient stimulation of T-cell responses due to ineffective antigen presentation. An approach to overcome these deficiencies is to modify tumor cells to express majo...

journal_title：Cancer gene therapy

authors： Hock RA,Reynolds BD,Tucker-McClung CL,Heuer JG

更新日期：1996-09-01 00:00:00

abstract：:A number of monoclonal antibodies (mAbs) have been studied for their ability to enhance immune responses. Although these antibodies are effective in pre-clinical and clinical studies, they are costly and have occasionally been associated with adverse effects such as autoimmunity and cytokine storm. Numerous studies ha...

journal_title：Cancer gene therapy

authors： Boczkowski D,Lee J,Pruitt S,Nair S

更新日期：2009-12-01 00:00:00

abstract：:Current oncolytic viruses exert only limited antitumor activity on their own. There is a need to increase their oncolytic capability. We evaluated the effect of a differentiating reagent, hexamethylene bisacetamide (HMBA), on the antitumor activity of a gamma(1)34.5-deficient herpes simplex virus type 1 (HSV-1) R849 f...

journal_title：Cancer gene therapy

authors： Naito S,Obayashi S,Sumi T,Iwai S,Nakazawa M,Ikuta K,Yura Y

更新日期：2006-08-01 00:00:00

abstract：:The clinical potential of tumor therapies must be evaluated using animal models closely resembling human cancers. We investigated the impact of locally delivered interferon-gamma (IFN-gamma) on primary hepatocarcinoma spontaneously developed by T-SV40 transgenic mice. A single intratumor injection of adenovirus IFN-ga...

journal_title：Cancer gene therapy

authors： Baratin M,Ziol M,Romieu R,Kayibanda M,Gouilleux F,Briand P,Leroy P,Haddada H,Rénia L,Viguier M,Guillet JG

更新日期：2001-03-01 00:00:00

abstract：:Gliomas express a higher amount of Fas than normal brain tissue. It is of interest to know whether expression of the Fas receptor is unfavorable to the antiapoptotic pathways in gliomas. In this study, we introduced the Fas gene via an adenovirus vector (Adeno-Fas) into the A-172, U251, and U-373 MG glioma cell lines,...

journal_title：Cancer gene therapy

authors： Shinoura N,Ohashi M,Yoshida Y,Kirino T,Asai A,Hashimoto M,Hamada H

更新日期：2000-02-01 00:00:00

abstract：:Lung metastases are a frequent complication of osteosarcoma and a treatment that would reduce the severity of this complication would be of great benefit to patients. We have used a formulation consisting of polyethyleneimine (PEI) and a p53 gene administered in aerosol to treat established lung micrometastases as a m...

journal_title：Cancer gene therapy

authors： Densmore CL,Kleinerman ES,Gautam A,Jia SF,Xu B,Worth LL,Waldrep JC,Fung YK,T'Ang A,Knight V

更新日期：2001-09-01 00:00:00

abstract：:The targeted expression of transgenes is one of the principal goals of gene therapy, and it is particularly relevant for the treatment of brain tumors. In this study, we examined the effect of the overexpression of human gas1 (growth arrest specific 1) and human p53 cDNAs, both under the transcriptional control of a p...

journal_title：Cancer gene therapy

authors： Benítez JA,Arregui L,Vergara P,Segovia J

更新日期：2007-10-01 00:00:00

abstract：:The aim of the present study is to identify the optimal anticancer agents for use in combination with gene therapy using wild-type (wt) p53 gene transfer. We used adenoviral vectors expressing human wt p53 (AdCAp53) and investigated the effects of wt p53 gene transfer in combination with 12 anticancer agents on a huma...

journal_title：Cancer gene therapy

authors： Osaki S,Nakanishi Y,Takayama K,Pei XH,Ueno H,Hara N

更新日期：2000-02-01 00:00:00

abstract：:An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

journal_title：Cancer gene therapy

authors： Sharifi M,Salehi R

更新日期：2020-02-01 00:00:00